A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer

Site 35 - Cleveland Clinic, Taussig Cancer Institute, Cleveland

Site 38 - Northwestern University, Feinberg School of Medicine, Northwestern University, Chicago

Site 41 - The START Center for Cancer Care, South Texas Oncology and Hematology, San Antonio

Site 32 - Swedish Medical Center, Swedish Cancer Institute (SCI),Cherry Hill Campus, Seattle

Site 42 - Dana-Farber Cancer Institute, EDDC, Boston

Site 81 - Bergonie unicancer, Nouvelle-Aquitaine, L'Institut Bergonie, Bordeaux

Site 80 - Centre Jean Bernard, Clinique Victor Hugo, Le Mans

Site 83 - Institut Paoli Calmettes (IPC), Marseille

Site 85 - Institut Curie, Paris

Site 82 - Institut de Cancerologie de Ouest (ICO), Saint-Herblain

Site 65 - Complexo Hospitalario Universitario A Coruña, A Coruña

Site 64 - Hospital Clinic de Barcelona (Hospital Clinic i Provincial), Barcelona

Site 68 -Hospital Universitario Vall d'Hebron, Barcelona

Site 61 - Institut Catala d'Oncologia (ICO), Hospital Duran i Reynals Location, L'Hospitalet de Llobregat

Site 62 - Universidad de Navarra, Clinica Universidad de Navarra (CUN), Madrid

Site 63 - South Texas Accelerated Research Therapeutics, CIOCC, Hospital Madrid Norte-Sanchinarro, Madrid

Site 66 - Hospital Clinico San Carlos, Madrid

Site 69 - Universidad de Navarra - Clinica Universidad de Navarra (CUN), Pamplona

Site 60 - NEXT Oncology EU Hospital Universitario Quiron Salud Madrid, Pozuelo de Alarcón

Site 67 - Universidad de Sevilla, Hospital Universitario Virgen Macarena, Seville

Site 12 - Belfast City Hospital, Belfast

Site 4 - The Christie NHS Foundation Trust, Manchester

Site 2 - Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford